Physician profile
Daniel Orme
NPI 1922660950
$10,124.23
in general payments reported to CMS, 2019-2025
31 companies · $8,286 in 2025
The $8,286 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $12.79 · 2023: $447 · 2024: $1,253 · 2025: $8,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,162 · Consulting Fee: $4,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,162.11 |
| Consulting Fee | $4,824.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,031.83 | 2021-2025 | |
| Emd Serono, INC. | $1,689.18 | 2024-2025 | |
| Tg Therapeutics, INC. | $788.77 | 2023-2025 | |
| Biogen, INC. | $565.18 | 2023-2025 | Tysabri, Vumerity, Tysabri |
| Abbvie INC. | $408.86 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $389.96 | 2024-2025 | |
| Argenx US, INC. | $286.09 | 2024-2025 | Vyvgart Hytrulo |
| Ani Pharmaceuticals, INC. | $264.17 | 2024-2025 | Purified Cortrophin Gel |
| Amgen INC. | $196.46 | 2024-2025 | Uplizna |
| Genentech USA, INC. | $190.36 | 2024-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Ucb, INC. | $174.07 | 2024-2025 | Rystiggo, Zilbrysq, Fintepla |
| Genentech, INC. | $118.75 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Mallinckrodt Hospital Products INC. | $116.70 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $116.70 | 2024-2025 | Ultomiris |
| Pfizer INC. | $92.02 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $90.04 | 2025 | Hizentra |
| Vanda Pharmaceuticals INC. | $89.78 | 2024-2025 | Ponvory |
| Axsome Therapeutics, INC. | $84.06 | 2024-2025 | Sunosi |
| Eisai INC. | $74.26 | 2024-2025 | |
| Celgene Corporation | $70.28 | 2024-2025 | Zeposia |
| Janssen Scientific Affairs, LLC | $65.85 | 2025 | |
| Cycle Pharmaceuticals INC | $36.27 | 2025 | Bafiertam, Tascenso Odt |
| Merz Pharmaceuticals, LLC | $32.12 | 2025 | Inbrija, Ampyra, Xeomin |
| Teva Pharmaceuticals USA, INC. | $24.24 | 2025 | Ajovy |
| E.R. Squibb & Sons, L.L.C. | $23.24 | 2024 | Zeposia |
| Jazz Pharmaceuticals INC. | $22.49 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $20.30 | 2024 | Dysport |
| Kedrion Biopharma, INC. | $18.02 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Sk Life Science, INC. | $15.43 | 2025 | |
| Lundbeck LLC | $14.45 | 2025 | Vyepti |
| Neurelis, INC. | $14.30 | 2025 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Orme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.